State of New Jersey Common Pension Fund D Sells 1,464 Shares of United Therapeutics Co. (NASDAQ:UTHR)

State of New Jersey Common Pension Fund D cut its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 8.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,439 shares of the biotechnology company's stock after selling 1,464 shares during the quarter. State of New Jersey Common Pension Fund D's holdings in United Therapeutics were worth $5,533,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Meritage Portfolio Management boosted its position in shares of United Therapeutics by 9.6% during the 3rd quarter. Meritage Portfolio Management now owns 1,289 shares of the biotechnology company's stock worth $462,000 after acquiring an additional 113 shares in the last quarter. Crossmark Global Holdings Inc. boosted its position in United Therapeutics by 20.4% in the third quarter. Crossmark Global Holdings Inc. now owns 3,584 shares of the biotechnology company's stock valued at $1,284,000 after buying an additional 608 shares in the last quarter. Colonial River Investments LLC acquired a new stake in United Therapeutics in the third quarter valued at approximately $435,000. Axxcess Wealth Management LLC acquired a new stake in United Therapeutics in the third quarter valued at approximately $435,000. Finally, Assetmark Inc. boosted its position in United Therapeutics by 56.9% in the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company's stock valued at $150,492,000 after buying an additional 152,249 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent research reports. Bank of America cut their price target on shares of United Therapeutics from $303.00 to $280.00 and set an "underperform" rating on the stock in a report on Thursday, August 1st. TD Cowen lifted their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a report on Monday, October 21st. LADENBURG THALM/SH SH boosted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Finally, HC Wainwright boosted their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $370.86.

United Therapeutics Trading Up 0.5 %

Shares of NASDAQ:UTHR traded up $2.18 during trading on Tuesday, reaching $402.62. The company had a trading volume of 151,037 shares, compared to its average volume of 463,336. The company has a fifty day moving average of $359.94 and a two-hundred day moving average of $324.54. The stock has a market capitalization of $17.98 billion, a P/E ratio of 17.59, a price-to-earnings-growth ratio of 1.20 and a beta of 0.56. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.38 EPS. As a group, equities research analysts predict that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $344.18, for a total value of $1,239,048.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company's stock, valued at approximately $44,743.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $344.18, for a total value of $1,239,048.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company's stock, valued at approximately $44,743.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 15,000 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $401.44, for a total transaction of $6,021,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $1,034,510.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 96,422 shares of company stock valued at $35,251,428 in the last quarter. Insiders own 11.90% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.